Vaccines specialist Intercell AG of Vienna, Austria, completed the acquisition of Pelias AG, gaining ownership of a Pseudomonas vaccine in Phase I clinical trials.
Pelias will remain a separate legal entity, operating as a subsidiary of Intercell AG. Apart from the Pseudomonas vaccine, Pelias has other vaccines programmes targeting hospital-acquired infections in development.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
